High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients.

Autor:	Rodríguez de la Concepción ML; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain., Ainsua-Enrich E; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain., Reynaga E; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Ávila-Nieto C; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain., Santos JR; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Roure S; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Mateu L; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain.; Universitat Autonoma de Barcelona, Cerdanyola Del Vallès, Spain.; CIBERes: Centro de investigaciones en Red de Enfermedades Respiratorias Del Instituto Carlos III, Madrid, Spain., Paredes R; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Puig J; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Jimenez JM; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain., Izquierdo-Useros N; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain., Clotet B; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain.; Chair in Infectious Diseases and Immunity, Centre for Health and Social Care Research (CESS), Faculty of Medicine. University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain.; Universitat Autonoma de Barcelona, Cerdanyola Del Vallès, Spain.; CIBERes: Centro de investigaciones en Red de Enfermedades Respiratorias Del Instituto Carlos III, Madrid, Spain., Pedro-Botet ML; Infectious Diseases Department, Fight Against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, Badalona, Spain.; Universitat Autonoma de Barcelona, Cerdanyola Del Vallès, Spain.; CIBERes: Centro de investigaciones en Red de Enfermedades Respiratorias Del Instituto Carlos III, Madrid, Spain., Carrillo J; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain jcarrillo@irsicaixa.es.
Jazyk:	angličtina
Zdroj:	Life science alliance [Life Sci Alliance] 2021 Jul 28; Vol. 4 (9). Date of Electronic Publication: 2021 Jul 28 (Print Publication: 2021).
DOI:	10.26508/lsa.202001009
Abstrakt:	The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19-affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid-binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status. (© 2021 Rodríguez de la Concepción et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu